Cashed-up Scancell aims at 'the UK solution' - proof of concept and acquisition
This article was originally published in Scrip
With the confirmation of second tranche payment of £2.85 million from Arana Therapeutics for an asset it sold in 2006, the UK immunology company, Scancell Holdings is now in a position to push towards its endgame of acquisition by a larger firm in search of a Phase II cancer vaccine asset and cancer vaccine platform.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.